Basic information about inhibitors

IPAD-DB ID	C00692
Name	Epigallocatechin-3-gallate（EGCG）
Category	Natural compounds
2D Structure
3D Structure
Molecular Formula	C 2 2 H 1 8 O 1 1
Molecular Weight	458.4 g/mol
IUPAC Name	[(2R, 3R)-5, 7-dihydroxy-2-(3, 4, 5-trihydroxyphenyl)-3, 4-dihydro-2H-chromen-3-yl] 3, 4, 5-trihydroxybenzoate
InChI	InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6, 18, 21, 23-30H, 7H2/t18-, 21-/m1/s1
InChIKey	WMBWREPUVVBILR-WIYYLYMNSA-N
Canonical SMILES	C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C9)O)O)O
PubChem CID	65064
DrugBank Accession Number	DB12116
CAS Registry Number	989-51-5

Biological activity data

Ki	-
EC50	-
IC50	-
Inhibition	-
Toxicity	-
ROS(reactive oxygen species)	-
Metal Chelating	-
BBB(blood-brain barrier)	-
Target Protein	Aβ1-42
Effects	(1) EGCG markedly promotes cleavage of the α-C-terminal fragment of APP and elevates the N-terminal APP cleavage product, soluble APP-α, (2)EGCG (20 μm) reduces Aβ generation from SweAPP N2a cells by 61% and from primary Tg APPsw-derived neuronal cells by 38% compared with untreated cells, (3)EGCG activates nonamyloidogenic processing of APP in SweAPP N2a cells, (4)intraperitoneally administered EGCG to Tg APPsw mice and found a significant reduction in cerebral Aβ levels concomitant with reduced β-amyloid plaques,
Research Models	N2a cells, APPswTg 2576 mice,
Main Source	-
Ref. Link

Physicochemical properties

Molecular Weight(Computed by SwissADME)	0
Hac(Computed by SwissADME)
Volume(Computed by ADMETlab 2.0)
Density(Computed by ADMETlab 2.0)
nRing(Computed by ADMETlab 2.0)
MaxRing(Computed by ADMETlab 2.0)
nHet(Computed by ADMETlab 2.0)
fChar(Computed by ADMETlab 2.0)
nRig(Computed by ADMETlab 2.0)
Flexibility(Computed by ADMETlab 2.0)
Stero Centers(Computed by ADMETlab 2.0)
LogS(Computed by ADMETlab 2.0)
LogD(Computed by ADMETlab 2.0)

ADMET properties

logP(Computed by ADMETlab 2.0)
TPSA(Computed by SwissADME)	0
Hbond Acceptor(Computed by SwissADME)	11
Hbond Donor(Computed by SwissADME)	8
Rotatable Bonds(Computed by SwissADME)

Pharmacokinetics

GI Absorption(Computed by SwissADME)	Low
BBB(blood-brain barrier) Permeant(Computed by SwissADME)	No
P-gp Substrate(Computed by SwissADME)	No
CYP1A2 Inhibitor(Computed by SwissADME)	No
CYP2C19 Inhibitor(Computed by SwissADME)	No
CYP2C9 Inhibitor(Computed by SwissADME)	No
CYP2D6 Inhibitor(Computed by SwissADME)	No
CYP3A4 Inhibitor(Computed by SwissADME)	No
log Kp(Skin Permeation)(Computed by SwissADME)	-8.27

Druglikeness

Lipinski(Computed by SwissADME)	2
Ghose(Computed by SwissADME)	0
Veber(Computed by SwissADME)	1
Egan(Computed by SwissADME)	1
Muegge(Computed by SwissADME)	3
Bioavailability Score(Computed by SwissADME)	0.17